KR20120055159A - A composition for reducing sleep induction time and prolonging sleeping time containing chrysanthemum indicum extract, and preparing method for the same - Google Patents
A composition for reducing sleep induction time and prolonging sleeping time containing chrysanthemum indicum extract, and preparing method for the same Download PDFInfo
- Publication number
- KR20120055159A KR20120055159A KR1020100116714A KR20100116714A KR20120055159A KR 20120055159 A KR20120055159 A KR 20120055159A KR 1020100116714 A KR1020100116714 A KR 1020100116714A KR 20100116714 A KR20100116714 A KR 20100116714A KR 20120055159 A KR20120055159 A KR 20120055159A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- extract
- sleep
- insomnia
- time
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 34
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims abstract description 9
- 230000006698 induction Effects 0.000 title abstract description 13
- 240000005250 Chrysanthemum indicum Species 0.000 title description 2
- 235000018959 Chrysanthemum indicum Nutrition 0.000 title description 2
- 230000036578 sleeping time Effects 0.000 title description 2
- 206010022437 insomnia Diseases 0.000 claims abstract description 38
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract description 37
- 230000006872 improvement Effects 0.000 claims abstract description 22
- 208000024891 symptom Diseases 0.000 claims abstract description 21
- 230000002265 prevention Effects 0.000 claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 235000014347 soups Nutrition 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 235000011511 Diospyros Nutrition 0.000 claims description 4
- 244000236655 Diospyros kaki Species 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 17
- 230000004622 sleep time Effects 0.000 abstract description 11
- 238000002360 preparation method Methods 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 238000004904 shortening Methods 0.000 abstract description 3
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 24
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 15
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 12
- 229960001412 pentobarbital Drugs 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 239000003814 drug Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 229940027779 persimmon extract Drugs 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000004941 influx Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- ZJQHPWUVQPJPQT-UHFFFAOYSA-N muscimol Chemical compound NCC1=CC(=O)NO1 ZJQHPWUVQPJPQT-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000002618 waking effect Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000000026 Pentaerythritol tetranitrate Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 244000223014 Syzygium aromaticum Species 0.000 description 2
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- -1 coatings Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000000517 effect on sleep Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- DSLLHVISNOIYHR-UHFFFAOYSA-M ethyl 2-(6-methoxyquinolin-1-ium-1-yl)acetate;bromide Chemical compound [Br-].COC1=CC=C2[N+](CC(=O)OCC)=CC=CC2=C1 DSLLHVISNOIYHR-UHFFFAOYSA-M 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000012432 gingerbread Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 불면 증상의 예방 및 개선용 조성물과 그의 제조방법에 관한 것으로서, 더욱 상세하게는 감국 추출물을 유효성분으로 사용함으로써 수면 유도시간을 단축하고 수면시간을 연장시키는 효과를 나타내는 불면증상의 예방 및 개선용 추출물과 그의 제조방법에 관한 것이다. The present invention relates to a composition for the prevention and improvement of insomnia symptoms and a method for manufacturing the same, and more particularly to the prevention and improvement of insomnia symptoms showing the effect of shortening the sleep induction time and prolong the sleep time by using the extract as an active ingredient It relates to a dragon extract and a preparation method thereof.
Description
본 발명은 감국 추출물을 유효성분으로 사용하여 수면 유도시간을 단축하고, 수면시간을 연장시키는 효과를 나타내게 한 불면증상의 예방 및 개선용 조성물과 그의 제조방법에 관한 것으로서, 감국 추출물이 세포 내로 클로라이드 이온(Cl-)의 유입을 촉진함을 확인하고, 이를 적용할 경우 개체의 수면 유도시간을 단축하며, 수면시간을 연장시키는데 유용하게 사용될 수 있는 불면증상의 예방 및 개선용 조성물과 그의 제조방법을 제공하고자 하는 것이다.
The present invention relates to a composition for the prevention and improvement of insomnia symptoms and a method for preparing the same, wherein the composition is prepared by using the extract as an active ingredient to shorten the sleep induction time and to prolong the sleep time. Cl - confirmed that promote the influx of), and reduce the surface inducing the object time when applying them, and to provide a sleep time for the prevention and improvement on that can be useful to extend insomnia a composition and a method of manufacturing the same will be.
현대사회에서는 많은 사람들이 스트레스와 불안, 초조 때문에 수면장애를 겪고 있지만, 그 기간이 짧고 약할 때에는 약물치료가 필요하지 않으나 업무를 수행하는데 지장을 초래하게 되면 약물치료가 필요하다. 통계에 의하면 성인의 약 15%가 불안증상에 의한 불면증 때문에 약물치료가 필요하다고 알려져 있으며, 나이가 많아질수록 불면증 환자는 더욱 증가한다고 알려져 있다. In modern society, many people suffer from sleep disorders due to stress, anxiety, and anxiety. However, when the period is short and weak, medication is not required. According to statistics, about 15% of adults are in need of drug treatment due to insomnia caused by anxiety symptoms. Increasing age increases the insomnia patients.
불면의 원인으로는 스트레스, 지나친 걱정, 긴장, 공포 등 다양하며, 치료약물로는 벤조디아제핀 계열의 약물과 세로토닌 효능약 등이 사용되고 있으나, 이러한 약물들은 장기간 사용하였을 때 내성 및 의존성이 형성되는 부작용이 심하여, 부작용이 적으면서 불안과 불면을 치료할 수 있는 약물을 개발하는 것이 필요하다.There are various causes of insomnia, such as stress, excessive anxiety, tension, and fear.Therapeutic drugs include benzodiazepines and serotonin agonists. In addition, it is necessary to develop drugs that can treat anxiety and insomnia with fewer side effects.
한편, 본 발명에서 제시하고자 하는 감국 추출물이 불면증상의 예방 및 개선에 효과가 있다는 사실은 어떠한 문헌에도 기재되거나 암시된 바가 없다.
On the other hand, the fact that the gakguk extract to be proposed in the present invention is effective in the prevention and improvement of insomnia symptoms are not described or implied in any literature.
이에 본 발명의 발명자들은 상기한 문제들을 해결하기 위하여 연구 노력한 결과, 감국 추출물이 수면 유도시간 단축 및 수면시간 연장 효과를 향상시킬 수 있음을 발견하고 본 발명을 완성하게 되었다. Accordingly, the inventors of the present invention have been researched to solve the above problems, and found that the gamguk extract can improve the effect of shortening the sleep induction time and extending the sleep time, thereby completing the present invention.
따라서, 본 발명은 수면 유도시간을 단축하고, 수면시간을 연장시키는데 효과적으로 사용할 수 있으며, 독성이 거의 없는 불면증 예방 및 개선용 조성물 및 그 제조방법을 제공하는 데에 그 목적이 있다.
Therefore, an object of the present invention is to provide a composition for preventing and improving insomnia and a method for manufacturing the same, which can be effectively used to shorten the sleep induction time and extend the sleep time.
상기한 목적을 달성하기 위한 일례로서 본 발명의 불면 증상의 예방 및 개선용 조성물은, 감국 추출물을 유효성분으로 포함하는 것을 특징으로 한다.As an example for achieving the above object, the composition for the prevention and improvement of insomnia symptoms of the present invention is characterized in that it comprises a gamguk extract as an active ingredient.
상기 감국 추출물은 조성물 중 유효량으로 50 mg/kg 이상 포함되는 것을 특징으로 한다. The persimmon extract is characterized in that it comprises at least 50 mg / kg in an effective amount in the composition.
상기한 과제를 해결하기 위한 본 발명의 다른 일례로서, 상기 불면 증상의 예방 및 개선용 조성물을 포함하는 기능성 식품을 특징으로 한다.As another example of the present invention for solving the above problems, a functional food comprising a composition for the prevention and improvement of the insomnia.
상기한 과제를 해결하기 위한 본 발명의 또 다른 일례로서 불면 증상의 예방 및 개선용 조성물의 제조방법은, 감국을 탄소수 1 내지 4의 저급알콜 40 내지 80 중량% 포함 수용액으로 추출, 여과, 농축 및 건조하여 감국 추출물을 얻는 과정을 포함하여 이루어지는 것을 특징으로 한다.
As another example of the present invention for solving the above problems, the method for producing a composition for the prevention and improvement of insomnia symptoms, extract, filtration, concentration and the like in the aqueous solution containing 40 to 80% by weight of lower alcohol having 1 to 4 carbon atoms It is characterized in that it comprises a process of obtaining the extract by drying the soup.
이하, 본 발명의 불면 증상의 예방 및 개선용 조성물과 그의 제조방법을 각 성분과 제조단계별로 구체적으로 설명한다.Hereinafter, the composition for the prevention and improvement of insomnia symptoms of the present invention and the preparation method thereof will be described in detail for each component and manufacturing steps.
먼저, 본 명세서 및 특허청구범위에 사용된 불면 또는 불면증은 상쾌하게 깨어나기에 충분하지 않은 감각을 의미하고, 우리나라 연간 전체 성인 가운데 약 15 % 정도에 영향을 주는 것으로 보고되고 있다. 이 용어는 임의의 및 모든 수면 상실의 유형 및 등급을 의미하는 것으로서 널리 사용된다. 또한, 개선(시킨다)은 수면 장애 및 정상적인 수면을 방해하는 기타 상태와 관련된 불면 및 기타 징후를 감소시키거나, 방지하거나(예를 들어, 예방), 역전시키거나(예를 들어, 경감시킴), 호전시키거나, 제어하거나 또는 잘 관리하는 것을 의미한다. First, insomnia or insomnia used in the present specification and claims mean a sense that is not enough to wake up refreshed, and is reported to affect about 15% of all adults in Korea annually. The term is widely used as meaning any and all types of sleep loss. In addition, the improvement may reduce, prevent (eg, prevent), reverse (eg, alleviate) or reduce insomnia and other symptoms associated with sleep disorders and other conditions that interfere with normal sleep, Means to improve, control or manage well.
감국(Chrysanthemum indicum L.)은 국화과(菊花科, Asteraceae)에 속하는 여러해살이풀로서 황국(黃菊)이라고도 한다. 주로 산에서 자라며, 10월에 꽃을 말려서 술에 넣어 마시거나, 어린잎은 나물로 사용하고 있다. 감국은 몸을 가볍게 하고 늙지 않게 하며 장수하게 하고, 근골을 장하게 하고 골수를 보하며 눈을 밝게 하며, 풍현두통(風睍頭痛)을 치료하며, 술을 마시고 깨지 않을 때 이용한다.Gamguk ( Chrysanthemum indicum L.) is a perennial herb belonging to the Asteraceae family, also known as Huangguk (黃菊). It grows mainly in the mountains, and in October, the flowers are dried and drunk, or young leaves are used as herbs. Gamguk is used to lighten the body, not to grow old, to longevity, to strengthen the musculature, to see the bone marrow, to brighten the eyes, to treat punghyun headache, and to drink and not wake up.
감국 추출물은, 감국을 탄소수 1 내지 4의 저급알콜 40 내지 80 중량% 포함 수용액으로 추출, 여과, 농축 및 건조하여 얻을 수 있으며, 불면 증상의 예방 및 개선용 조성물의 제조방법은 상기한 감국 추출물을 얻는 과정을 포함하여 이루어지는 것을 특징으로 한다.The gamguk extract can be obtained by extracting, filtering, concentrating and drying the gamguk in an aqueous solution containing 40 to 80% by weight of lower alcohol having 1 to 4 carbon atoms. It is characterized by comprising the process of obtaining.
더욱 구체적으로, 감국과 탄소수 1 내지 4의 저급알콜 40 내지 80 중량% 포함 수용액을 1 : 5 내지 20 중량비 비율로 혼합 및 침지한 후, 초음파 추출, 환류추출, 가열추출(40 내지 80 ℃) 등의 다양한 방법으로 추출하는데, 이때, 추출 단계는 2 내지 5 회 반복 수행하는 것이 감국 유효성분 추출의 수득율 측면에서 좋다. 알콜 수용액에 의하여 추출된 결과물은 멸균한 후 여과한다. 영양성분의 유지와 멸균 등을 고려하여 고압멸균할 경우 기타 영양성분의 변성을 최소화할 수 있으며 멸균 효과를 얻을 수 있고, 감압여과할 경우 수율 측면에서 바람직하다. 여과한 여액은 다양한 방법으로 농축 및 건조한 후 사용할 수 있으며, 감압농축이나 동결건조를 선호하는 경향이 있다. More specifically, after mixing and immersing the aqueous solution containing 40-80% by weight of lower alcohol with 1 to 4 carbon atoms in a ratio of 1: 5 to 20% by weight, ultrasonic extraction, reflux extraction, heating extraction (40 to 80 ℃), etc. Extraction is carried out in various ways, wherein the extraction step is repeated 2 to 5 times in terms of yield of the extraction of the effective ingredient in the country. The resultant extracted by the aqueous alcohol solution is sterilized and filtered. High-pressure sterilization in consideration of the maintenance and sterilization of nutrients can minimize the denaturation of other nutrients, and can achieve sterilization effects. The filtrate can be concentrated and dried in a variety of ways and used, and tends to prefer reduced pressure concentration or lyophilization.
상기 감국 추출물의 제조시 여과, 멸균, 농축 및 건조는 당 업계에서 통상적으로 허용되는 방법을 적의 채택하여 적용할 수 있으며 이들의 선택에 의하여 본 발명이 한정되는 것은 아니다.Filtration, sterilization, concentration and drying in the preparation of the gamgukchi extract can be applied by appropriately adopted methods commonly accepted in the art and the present invention is not limited by their selection.
이러한 감국 추출물은 조성물 중 유효량으로 50 mg/kg 이상, 구체적으로는 50 내지 500 mg/kg 포함되는 경우 불면 증상의 개선 및 예방 효과의 발현과 경제적인 측면에서 바람직하다. 감국 추출물의 함량이 높은 경우에는 감국 특유의 향이 취식자에 거슬릴 수 있다.Such a gamguk extract is preferred in terms of economics and expression of the improvement and prevention of insomnia symptoms when in an effective amount of 50 mg / kg or more, specifically 50 to 500 mg / kg included in the composition. If the content of persimmon extract is high, the flavor of the persimmon soup may be uncomfortable.
불면 증상의 개선은 정량적 및 정성적으로 측정될 수 있다. 예를 들어, 정성적인 경우, 불면 증상의 개선은 취침 시간에 더 빨리 잠드는 것, 밤중에 깨어있는 빈도의 감소, 적당한 시간에서의 기상, 및 개체가 다음날 상쾌한 기분을 느낄 수 있게 하는 양질의 수면을 취하는 것을 포함하나, 이것만으로 제한되지는 않는 임의의 개수의 인자에 의해 측정될 수 있다. Improvement of insomnia symptoms can be measured both quantitatively and qualitatively. For example, in qualitative cases, improving insomnia may result in faster sleep at bedtime, reduced frequency of waking in the night, waking up at the right time, and a good night's sleep that allows the individual to feel refreshed the next day. It can be measured by any number of factors, including but not limited to taking.
불면 증상의 정량적인 개선을 측정하기 위하여 사용될 수 있는 인자는 수면 효율 증가를 나타내는 수면 다원 검사, 단계 1과 상반되는 단계 2 내지 4 에서와 같은 수면의 보다 깊은 단계에서 수면 상태로 있는 더 많은 시간, 주기적인 인지 운동 회수의 감소를 포함하지만, 이것만으로 제한되는 것은 아니다.Factors that can be used to measure the quantitative improvement of insomnia symptoms include sleep polymorphism tests that indicate increased sleep efficiency, more time to sleep at deeper levels of sleep, such as
본 발명자는 감국 추출물이 수면 유도시간을 단축하거나 수면시간을 연장시키는 효과가 있음을 확인하였다. 또한 이의 작용기전을 규명하고자 신경세포 내 클로라이드 이온 (Cl-) 양을 측정한 결과 클로라이드 이온 (Cl-) 양이 증가하는 것을 확인하였다. 또한 글루타민산 탈탄산효소(glutamic acid decarboxylase, GAD) 발현을 측정한 결과 GAD 단백질양이 증가하는 것을 확인하였다. The present inventors confirmed that the extract of Gingerbread has an effect of shortening the sleep induction time or extending the sleep time. Also within the chloride ion (Cl -) nerve to investigate the mechanism of action thereof, the cell was confirmed that the amount of chloride ions increase results of measuring the amount (Cl). In addition, the expression of glutamic acid decarboxylase (GAD) was measured, and it was confirmed that the amount of GAD protein was increased.
본 발명에 따른 불면 증상의 예방 및 개선용 조성물은 감국 추출물 이외에 약제학적으로 허용 가능한 담체를 포함할 수도 있으며, 이러한 담체로는 부형제, 결합제, 활택제, 붕괴제, 피복제, 유화제, 현탁제, 용제, 안정화제, 흡수조제, 주사용수, 및 등장화제 등으로 이루어진 군으로부터 선택된 하나 이상의 담체를 예로 들 수 있다. The composition for the prevention and improvement of insomnia according to the present invention may include a pharmaceutically acceptable carrier in addition to the gamguk extract, such carriers, excipients, binders, lubricants, disintegrants, coatings, emulsifiers, suspensions, And at least one carrier selected from the group consisting of solvents, stabilizers, absorption aids, water for injection, isotonic agents and the like.
본 발명에 따른 불면 증상의 예방 및 개선용 조성물은 경구 또는 주사제 제제로 제형화 될 수도 있으며, 바람직하게는, 경구제제로 제형화 될 수 있다. 이러한 경구 제제로서 구체적으로 과립제, 정제, 캡슐제, 액제 등이 있다.The composition for the prevention and improvement of insomnia according to the present invention may be formulated in oral or injectable preparations, preferably in oral preparations. Specific examples of such oral preparations include granules, tablets, capsules, and liquids.
본 발명에 따른 불면 증상의 예방 및 개선용 조성물의 투여횟수 및 투여량은 환자의 나이, 성별, 체중에 따라 달라질 수 있으나, 성인 남자(체중 70 kg)를 기준으로 하고, 감국 추출물의 혼합물 중량의 측면에서 10 ~ 5,000 mg/일, 보다 바람직하게는 50 ~ 2,000 mg/일인 것이 바람직하다.The frequency and dosage of the composition for preventing and improving insomnia according to the present invention may vary depending on the age, sex, and weight of the patient, but based on the adult male (70 kg body weight), In view of the above, it is preferred that it is 10 to 5,000 mg / day, more preferably 50 to 2,000 mg / day.
본 발명의 불면 증상의 예방 및 개선용 조성물을 이루는 감국 추출물은 그 원료가 오래전부터 식재료 또는 약재료로 음용되어오던 것으로 그 독성 및 안정성이 입증되어 있고, 기존의 불면 증상의 예방이나 치료를 위하여 사용되어 오던 조성물과 달리 독성에 의한 중독이나 의존증을 야기시키지 않는 또 다른 장점이 있다.The gamgukg extract forming the composition for the prevention and improvement of insomnia symptoms of the present invention has been proven to be toxic and stable as a raw material has been eaten as a food or medicine for a long time, and is used for the prevention or treatment of existing insomnia symptoms Unlike the old composition, there is another advantage that does not cause poisoning or dependency due to toxicity.
본 발명의 불면 증상 예방 및 개선용 조성물을 불면 증상의 예방 및 개선용 경구용 제제로 제조하여 섭취할 수 있으며, 식품 고유의 식미를 해치지 않는 범위에서 다양한 형태의 기능성 식품으로 제조하여 섭취할 수 있다. 이러한 기능성 식품의 비제한적인 예로는 비스켓, 사탕, 차, 건강보조 식품류 등을 들 수 있다.The composition for preventing and improving insomnia symptoms of the present invention can be prepared and ingested as an oral preparation for preventing and improving insomnia symptoms, and can be prepared and consumed in various forms of functional foods in a range that does not impair the intrinsic taste of food. . Non-limiting examples of such functional foods include biscuits, candy, tea, dietary supplements and the like.
또한, 본 발명에 따른 불면 증상의 예방 및 개선용 조성물은 인간 뿐 아니라 쥐, 개, 토끼, 고양이, 닭, 소, 돼지 등의 온혈 동물에 적용되어 불면 증상의 개선을 위하여 응용될 수 있다.
In addition, the composition for the prevention and improvement of insomnia according to the present invention can be applied to the warm-blooded animals such as rats, dogs, rabbits, cats, chickens, cattle, pigs as well as humans can be applied for the improvement of insomnia symptoms.
상술한 바와 같이 본 발명의 불면 증상의 예방 및 개선용 조성물에 의하면, 인체에 안전하고 독성이 적으며, 신경세포 내 클로라이드 이온 (Cl-)의 유입을 뚜렷하게 촉진하는 경향을 보임을 알 수 있다. As described above, according to the composition for preventing and improving insomnia symptoms of the present invention, it can be seen that the human body is safe and less toxic and has a tendency to clearly promote the influx of chloride ions (Cl − ) into neurons.
이에 따라 본 발명의 불면 증상의 예방 및 개선용 조성물은 수면유도시간을 단축하고 수면시간을 연장시킬 수 있어 불면증상을 예방하고 개선하는 효과를 기대할 수 있다.
Accordingly, the composition for the prevention and improvement of insomnia symptoms of the present invention can shorten the sleep induction time and prolong the sleep time can be expected to the effect of preventing and improving insomnia symptoms.
도 1은 감국 추출물이 펜토바르비탈 유도 수면에 미치는 효과를 나타낸 그래프이다(*P < 0.05, ***P < 0.005)[(A)는 수면시간에 미치는 효과를 나타낸 것이고, (B)는 수면유도시간에 미치는 효과를 나타낸 것이다].
도 2은 클로라이드 유입(Chloride influx)에 대한 감국 추출물(ECF)의 효과를 나타낸 그래프이다(PENT: pentobarbital. *P < 0.05, ***P < 0.005, compared to the control).
도 3은 글루타민산 탈탄산효소(GAD)에 대한 감국 추출물의 효과를 나타낸 그래프이다(PENT : pentobarbital. *P < 0.05, compared to the control)1 is a graph showing the effect of the extract of gamguk on pentobarbital induced sleep (* P <0.05, *** P <0.005) [(A) shows the effect on sleep time, (B) Effect on induction time].
Figure 2 is a graph showing the effect of the extract (ECF) on chloride influx (PENT: pentobarbital. * P <0.05, *** P <0.005, compared to the control).
Figure 3 is a graph showing the effect of the extract of gamguk on glutamic acid decarboxylase (GAD) (PENT: pentobarbital. * P <0.05, compared to the control)
이하, 본 발명을 실시예 등에 의거하여 구체적으로 설명하겠는바, 본 발명이 다음 실시예 등에 의하여 한정되는 것은 아니다.
Hereinafter, the present invention will be described in detail with reference to Examples and the like, but the present invention is not limited to the following Examples and the like.
실시예Example 1. One. 감국Country 추출물의 제조 Preparation of Extract
감국을 구입하여 건조시킨 후 건조된 감국과 70% 에탄올(40 내지 80 ℃)을 1 : 4 중량비 비율로 혼합하여 2회 가열 추출한 다음 여과하고, 여액을 감압농축 및 동결건조하여 감국 추출물을 수득하였다.
After purchasing and drying the persimmon soup, the dried persimmon soup and 70% ethanol (40-80 ° C.) were mixed at a ratio of 1: 4 by weight, and extracted twice by heating. .
실시예Example 2. 2. 펜토바르비탈로Pentobarbital 유도한 생쥐의 수면유도시간 및 수면시간 측정 Measurement of Sleep Induction Time and Sleep Time in Mice Induced
생쥐(대한실험동물에서 구입한 ICR계 생쥐로서 평균 체중 20 g의 수컷)는 펜토바르비탈 투여 전 24 시간 동안 사료를 주지 않고 굶겼으며, 그 후 펜토바르비탈 42 mg/kg을 복강으로 투여하였다. 수면은 정향반사가 소실되는 시점으로 했으며, 15분 이내에 수면을 취하지 않는 동물은 시험에서 배제하였고, 깨는 시간은 동물이 정향으로 돌아오는 시간으로 정하였다. Mice (males with an average body weight of 20 g, purchased from Korean experimental animals) were starved for 24 hours prior to pentobarbital administration, followed by intraperitoneal administration of pentobarbital 42 mg / kg. Sleep was the point at which clove reflections disappeared, animals not sleeping within 15 minutes were excluded from the test, and waking time was defined as the time for the animals to return to cloves.
상기 실시예 1에 의하여 수득된 감국 추출물의 함량을 달리하여 투여하였을 경우 그 사용량에 따라 생쥐에서 펜토바르비탈로 유도한 수면 유도시간과 수면시간에 미치는 효과를 다음 도 1에 나타내었다. When the content of the gakguk extract obtained in Example 1 was administered in different amounts, the effects on pentobarbital-induced sleep induction time and sleep time according to the amount of use were shown in FIG. 1.
상기 도 1에 나타낸 바와 같이, 감국 추출물 20, 50 및 100 mg/kg을 투여하였을 때 수면시간은 50 및 100mg/kg을 투여하였을 때 대조군에 비해 유의성 있게 증가되었으며(A), 수면유도시간은 대조군에 비해 50mg/kg 투여하였을 때의 대조군에 비해 유의성 있게 증가되었다(B).
As shown in FIG. 1, the administration time of 20, 50 and 100 mg / kg of the extract of Gamguk was significantly increased compared to the control group when 50 and 100 mg / kg was administered (A), and the sleep induction time was the control group. Compared to the control group when administered 50 mg / kg compared to the significantly increased (B).
또한, 감국 추출물이 펜토바르비탈 최소 수면용량(28 mg/kg)의 수면에 미치는 효과는 다음 표 1에 나타내었다. In addition, the effect of the gamguk extract on the sleep of the pentobarbital minimum sleeping dose (28 mg / kg) is shown in Table 1 below.
1) Muscimol : 대조약물
2) ECF : 감국 추출물 * P <0.05, ** P <0.01, *** P <0.005 vs. Control
1) Muscimol: reference drug
2) ECF: Gammon Extract
상기 표 1에 나타낸 바와 같이 펜토바르비탈 최소 농도로 유도한 수면 증가 효과를 측정한 결과, 감국 추출물은 수면을 유도하는 최소 용량의 펜토바르비탈과 병용 투여한 후 펜토바르비탈의 수면 동물의 수를 증가시켰다. 이는 감국 추출물이 수면제와 함께 사용할 경우 증강효과를 나타내는 것을 보여준다. As shown in Table 1 above, as a result of measuring the sleep increase effect induced by the minimum concentration of pentobarbital, the gamguk extract was administered in combination with the minimum dose of pentobarbital to induce sleep. Increased. This shows that the extract of Gam-guk shows an enhancement effect when used with sleeping pills.
한편, 펜토바르비탈 28 mg/kg은 15마리의 동물 중 6마리가 수면을 취하게 되는데 감국 추출물을 병용하면 수면 동물의 수가 용량 의존적으로 증가하며 감국 추출물 100 mg/kg에서 13마리 중 11마리가 수면을 하였다.
On the other hand, pentobarbital 28 mg / kg of 6 animals sleep in 15, and when combined with the gamguk extract, the number of sleeping animals increases dose-dependently, 11 out of 13 at 100 mg / kg of gamguk extract Sleep.
실시예Example 3. 신경세포 분리 배양 및 3. Neuronal cell culture and 세포내Intracellular 클로라이드 이온( Chloride ions ( ClCl -- )의 측정 )
임신 8일째의 흰쥐 (대한실험동물에서 구입한 SD계 흰쥐로서 평균 체중 200g의 암컷)에서 꺼낸 태아의 뇌로부터 소뇌를 제거하고, 뇌척수막을 떼어내 신경세포를 분리한 후, 분리된 신경세포를 5% 탄산가스 배양기에서 18 내지 24시간 배양한 다음 사이토신 아라비노푸라노사이드 (cytosine arabinofuranoside)를 첨가해 비신경 세포의 성장을 막고, 6 내지 12 일 동안 배양하여 클로라이드 이온 (Cl-) 측정에 사용하였다.The cerebellum was removed from the brain of the fetus from 8 days of pregnancy (SD rats purchased from Korean experimental animals, with an average body weight of 200 g), the cerebrospinal fluid was removed, and the neurons were separated. Incubate for 18 to 24 hours in a% carbon dioxide gas incubator, and then add cytosine arabinofuranoside to prevent growth of non-neuronal cells and incubate for 6 to 12 days to measure chloride ions (Cl − ) It was.
클로라이드 이온 (Cl-)의 측정은 신경세포에 엠큐에이이 (MQAE) 용액을 처리하여 하룻밤 방치한 후 클로라이드 이온 완충액을 섞어 5분 동안 배양한 다음, 형광측정기로 클로라이드 이온 (Cl-)을 측정하였으며, 그 결과를 도 2에 나타내었다. Chloride ion (Cl -) of the measurement is this (MQAE) one was treated with a solution mixed with a chloride ion buffer was allowed to stand overnight incubation for 5 minutes, a chloride ion as a fluorescent measuring instrument (Cl -) in emkyu the neurons was measured The results are shown in FIG.
도 2에 나타낸 바와 같이, 감국 추출물 1, 2 및 4μg/ml 처리하였을 때, 4μg/ml 처리하였을 때 대조군에 비해 세포내 클로라이드 이온 (Cl-)양이 증가하였다.
Also, in a chloride ion (Cl -) cells compared to control when, hayeoteul 4μg / ml when processed hayeoteul gamguk extracts 1, 2, and 4μg / ml treatment as shown in Fig. 2, the amount was increased.
실시예Example 4. 4. 글루타민산Glutamic acid 탈탄산효소Decarboxylase ( ( glutamicglutamic acidacid decarboxylasedecarboxylase , , GADGAD ) 65/67 ) 65/67 발현양Expression amount 측정 Measure
생쥐에 감국 추출물 100 mg/kg을 경구로, 펜토바르비탈 40 mg/kg을 복강으로 3일간 투여하였다. 생쥐 뇌의 해마 부분을 분리하여 완충용액으로 초음파조직분쇄기로 분쇄하였다. 각 분쇄물들을 20,000 X g 의 속도로 20분간 원심분리 한 후 동등한 양의 단백질을 웨스턴블로팅 (western blotting) 하여, 글루타민산 탈탄산효소 (glutamic acid decarboxylase, GAD)의 발현양을 측정하였다. 그 결과를 도 3에 나타내었다.Mice were dosed orally with 100 mg / kg of gamguk extract and 40 mg / kg of pentobarbital intraperitoneally for 3 days. The hippocampus of the mouse brain was separated and crushed with an ultrasonic tissue grinder with buffer. After centrifugation of each of the pulverized 20 minutes at a rate of 20,000 X g, the amount of protein was western blotting to measure the expression of glutamic acid decarboxylase (GAD). The results are shown in Fig.
도 3에 나타낸 바와 같이 감국추출물 투여군에서 대조군에 비해 글루타민산 탈탄산효소 (glutamic acid decarboxylase, GAD)의 발현양이 증가하였다.
As shown in FIG. 3, the expression level of glutamic acid decarboxylase (GAD) was increased in the gakg extract administration group compared to the control group.
상기한 결과로부터, 감국 추출물을 투여하였을 때, 글루타민산 탈탄산효소의 발현이 증가되어, 신경세포내 클로라이드 이온 (Cl-)의 유입이 촉진됨으로써, 수면유도시간 단축 및 수면시간 연장작용이 나타남을 유추할 수 있다.
From the above results, it was inferred that the administration of gamguk extract increased the expression of glutamate decarboxylase and promoted the influx of chloride ions (Cl − ) in neurons, resulting in a shorter sleep induction time and longer sleep time. can do.
실시예Example 5. 약제학적 조성물의 제조 5. Preparation of Pharmaceutical Composition
하기 조성에 따라서 각각 정제, 캡슐제 및 산제를 제조하였다.Tablets, capsules, and powders were prepared according to the following compositions, respectively.
1) 정제1) tablets
감국 추출물 250.0mgPersimmon Extract 250.0mg
유당 500.0mgLactose 500.0mg
탈크 5.0mgTalc 5.0mg
마그네슘 스테아레이트 1.0mg
Magnesium Stearate 1.0mg
2) 캡슐제2) Capsule
감국 추출물을 체질하여 부형제와 혼합한 후, 젤라틴 캡슐 중에 하기 조성에 따라 충전함으로써 캡슐제를 제조하였다.After sieving the mixture with the excipient and sieved, the capsule was prepared by filling the gelatin capsule according to the following composition.
감국 추출물 250.0mgPersimmon Extract 250.0mg
전분 1500 10.0mgStarch 1500 10.0mg
마그네슘 스테아레이트 1.0mg
Magnesium Stearate 1.0mg
3) 산제3) powder
하기 성분을 통상의 산제 제조 방법으로 혼합하고, 봉지에 넣어 밀봉한 후 산제를 제조하였다. The following components were mixed by a conventional powder preparation method, put into a bag, sealed, and powder was prepared.
감국 추출물 250.0mgPersimmon Extract 250.0mg
유당 100.0mgLactose 100.0 mg
탈크 5.0mg
Talc 5.0mg
실시예Example 6. 건강보조 식품의 제조 6. Manufacturing of dietary supplements
하기 성분을 물과 혼합하여 통상의 방법으로 음료를 제조하되, 총 100ml로 맞춘 후 95 ℃에서 15초간 살균 및 냉각하여 드링크제를 제조하였다.The following ingredients were mixed with water to prepare a beverage in a conventional manner, and adjusted to 100 ml in total, and then sterilized and cooled at 95 ° C. for 15 seconds to prepare a drink.
감국 추출물 500.0mg500.0mg of Korean soup extract
구연산 1000.0mgCitric Acid 1000.0mg
아라비아검 1000.0mgGum arabic 1000.0mg
설탕 5000.0mg
Sugar 5000.0mg
이상에서 설명한 본 발명은 전술한 실시예 및 첨부된 도면에 의해 한정되는 것이 아니고, 본 발명의 기술적 사상을 벗어나지 않는 범위 내에서 여러 가지 치환, 변형 및 변경이 가능함은 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 명백할 것이다.
The present invention described above is not limited to the above-described embodiment and the accompanying drawings, and various substitutions, modifications, and changes are possible within the scope without departing from the technical spirit of the present invention. It will be evident to those who have knowledge of.
도 1에서 (A)는 수면시간에 미치는 효과를 나타낸 것이고, (B)는 수면유도시간에 미치는 효과를 나타낸 것이며, 도 2에서 신경세포내 클로라이드 이온 (Cl-)의 양에 미치는 효과를 나타낸 것이며, 도 3에서 글루타민산 탈탄산효소 (glutamic acid decarboxylase, GAD)의 발현양에 미치는 효과를 나타낸 것이다.In Figure 1 (A) depicts the effect on the sleeping time, (B) will showing the effect on sleep induction time, in Figure 2 in a chloride ion (Cl -) neurons will showing the effect on the amount of , Figure 3 shows the effect on the expression level of glutamic acid decarboxylase (GAD).
Claims (4)
A composition for the prevention and improvement of insomnia, characterized in that it comprises a extract of gamgu.
상기 감국 추출물은 조성물 중 유효량으로 50 mg/kg 이상 포함되는 것을 특징으로 하는 불면 증상의 예방 및 개선용 조성물.
The method according to claim 1,
The gamguk extract composition for the prevention and improvement of insomnia symptoms characterized in that it comprises at least 50 mg / kg in an effective amount in the composition.
Food comprising a composition for preventing and improving insomnia symptoms of claim 1.
Method of producing a composition for the prevention and improvement of insomnia, characterized in that it comprises the step of extracting, filtering, concentrating and drying the persimmon soup with an aqueous solution containing 40 to 80% by weight of lower alcohol having 1 to 4 carbon atoms.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100116714A KR20120055159A (en) | 2010-11-23 | 2010-11-23 | A composition for reducing sleep induction time and prolonging sleeping time containing chrysanthemum indicum extract, and preparing method for the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100116714A KR20120055159A (en) | 2010-11-23 | 2010-11-23 | A composition for reducing sleep induction time and prolonging sleeping time containing chrysanthemum indicum extract, and preparing method for the same |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20120055159A true KR20120055159A (en) | 2012-05-31 |
Family
ID=46270780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100116714A KR20120055159A (en) | 2010-11-23 | 2010-11-23 | A composition for reducing sleep induction time and prolonging sleeping time containing chrysanthemum indicum extract, and preparing method for the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20120055159A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104324210A (en) * | 2014-09-23 | 2015-02-04 | 黄厚生 | Traditional Chinese medicine composition with health care function and preparation method thereof |
CN105012798A (en) * | 2015-08-07 | 2015-11-04 | 金冰 | Health-care product for preventing and treating sub-health and preparing method thereof |
-
2010
- 2010-11-23 KR KR1020100116714A patent/KR20120055159A/en not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104324210A (en) * | 2014-09-23 | 2015-02-04 | 黄厚生 | Traditional Chinese medicine composition with health care function and preparation method thereof |
CN105012798A (en) * | 2015-08-07 | 2015-11-04 | 金冰 | Health-care product for preventing and treating sub-health and preparing method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101789424B1 (en) | Medicinal-Herb Composition Comprising Chinese matrimony vine Proving Insomniac and the Method of Making the Same | |
EP1629837A1 (en) | Antistress agent | |
KR101775087B1 (en) | A composition for the prevention or treatment of stress or depression containing mulberrofuran G, sanggenon G and sanggenol A | |
KR102171518B1 (en) | Composition for Preventing or Treating Muscle Atrophy Comprising Lycii Radicis Cortex | |
KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
US11439603B2 (en) | Compositions for ameliorating, preventing or treating somnipathy including phloroglucinol as active ingredient and compositions for suppressing intolerance to or alleviating side effects of agonist at benzodiazepine binding site of GABA-A receptor including phloroglucinol as active ingredient | |
KR101474749B1 (en) | Composition for anxiolitic, anti-convulsant, anti-depressant or sleep-improving effect comprising shellfish extract as an effective component | |
KR20120055159A (en) | A composition for reducing sleep induction time and prolonging sleeping time containing chrysanthemum indicum extract, and preparing method for the same | |
KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
KR20210047414A (en) | A composition for the prevention, improvement or treatment of sleep disorders containing Curcuma longa extract | |
KR102262759B1 (en) | A composition for reducing side effects of GABAA receptor agonist, comprising phloroglucinol as an effective ingredient | |
KR101041044B1 (en) | A composition for reducing sleep induction time and prolonging sleeping time, and a method for preparing the same | |
KR101568044B1 (en) | Composition reducing anxiety and stress | |
KR101769972B1 (en) | A composition for improving, preventing and treating pulmonary disease comprising herb extract | |
KR102245027B1 (en) | Composition for improving sleep disorder containing lettuce and Scutellariae extract as an active ingredient | |
KR102501557B1 (en) | A composition for the prevention, improvement or treatment of sleep disorders or insomnia with reduced side effects of GABAA receptor agonist, containing Glehnia littoralis extract | |
KR20150005482A (en) | Composition containing extract of dendropanax morbifera the improvement and remedial of insominia | |
KR20160045256A (en) | A composition comprising an extract of Hippophae rhamnoides for treating or preventing a physiological stress, depression or dementia | |
KR101457442B1 (en) | A composition for histamine receptor antagonist comprising gamma-oryzanol as an effective ingredient | |
KR20140056651A (en) | A composition for histamine receptor antagonist comprising fatty acids as an effective ingredient | |
CN113181205B (en) | Pharmaceutical composition comprising NMN and use thereof | |
KR20110064917A (en) | A composition for the prevention and treatment of depression containing the extract of Conical flower as an active ingredient | |
KR101113978B1 (en) | Composition for improving erectile dysfunction and erection maintenance comprising the extract of Polygala tenuifolia as an active ingredient | |
KR20120134770A (en) | Composition for inhibiting obesity containing shiso leaf extract | |
KR101973000B1 (en) | Pharamceutical or food composition containing mono glycerides as active ingradeient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20101123 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20121019 Patent event code: PE09021S01D |
|
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20130402 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20121019 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |